Paper Details

  1. Home
  2. Paper Details

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Author: AbbasRichat, AwadaAhmad, BadweRajendra, BursteinHarold J, DirixLuc Y, JiangZefei, JiaoShunchang, ParidaensRobert, PowellChristine, RanadeAnantbhushan, SchwartzGary, SunYan, TanAntoinette R, TurnbullKathleen, VermetteJennifer, ZacharchukCharles

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This open-label, multicenter, phase II trial evaluated the efficacy and safety of neratinib, a pan-ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. Neratinib showed promising efficacy in both those with and those without prior trastuzumab treatment.
Paper Details　
Original Abstract of the Article :
Neratinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor. The efficacy and safety of neratinib were evaluated in two cohorts of patients with advanced ErbB2-positive breast cancer-those with and those without prior trastuzumab treatment-in an open-label, multicenter, phase II t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2009.25.8707

データ提供：米国国立医学図書館（NLM）

Neratinib: An Irreversible ErbB Receptor Tyrosine Kinase Inhibitor for Advanced ErbB2-Positive Breast Cancer

This research investigates the efficacy and safety of neratinib, an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. The open-label, multicenter, phase II trial evaluated neratinib in two cohorts of patients: those with and those without prior trastuzumab treatment. The study aimed to assess the potential benefits and risks of neratinib in this specific patient population.

Neratinib: A Potential Weapon in the Fight Against ErbB2-Positive Breast Cancer

The study provides valuable insights into the efficacy and safety of neratinib in patients with advanced ErbB2-positive breast cancer. While further research is needed to fully understand its long-term effects, neratinib holds promise as a potential treatment option for this challenging disease.

Navigating Treatment Options: A Personalized Approach to Breast Cancer Care

This study highlights the importance of personalized treatment approaches in breast cancer care. It underscores the need for careful consideration of a patient's individual characteristics, including prior treatment history, when determining the most appropriate therapeutic strategy. Open communication with your healthcare provider is crucial in navigating the complex landscape of breast cancer treatment options.

Dr. Camel's Conclusion

This phase II trial provides encouraging evidence for neratinib's potential as a treatment option for advanced ErbB2-positive breast cancer. While further research is necessary to fully evaluate its long-term efficacy and safety, neratinib offers a promising avenue for personalized treatment strategies in this challenging disease.

Date :
  1. Date Completed 2010-04-07
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

20142587

DOI: Digital Object Identifier

10.1200/JCO.2009.25.8707

Related Literature

Article Analysis
・Side Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.